Chongqing Pharscin Pharmaceutical Co Ltd (002907) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.000x

Based on the latest financial reports, Chongqing Pharscin Pharmaceutical Co Ltd (002907) has a cash flow conversion efficiency ratio of 0.000x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥833.94K ≈ $122.03K USD) by net assets (CN¥1.71 Billion ≈ $250.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 002907 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Chongqing Pharscin Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Chongqing Pharscin Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Chongqing Pharscin Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Chongqing Pharscin Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Pexip Holding ASA OL:PEXIP	0.196x
Shanghai Research Institute of Building Sciences Group Co. Ltd A SHG:603153	N/A
Changchun Faway Automobile Components Co Ltd SHG:600742	0.066x
Cresud SA BA:CRES	-0.021x
Patriot Battery Metals Inc AU:PMT	0.001x
Jaya Real Property Tbk JK:JRPT	0.014x
Seneca Foods Corp A NASDAQ:SENEA	0.044x
Argo Properties NV TA:ARGO	0.019x

Annual Cash Flow Conversion Efficiency for Chongqing Pharscin Pharmaceutical Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Chongqing Pharscin Pharmaceutical Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Chongqing Pharscin Pharmaceutical Co Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥1.66 Billion ≈ $242.91 Million	CN¥161.77 Million ≈ $23.67 Million	0.097x	-28.12%
2023-12-31	CN¥1.62 Billion ≈ $236.75 Million	CN¥219.34 Million ≈ $32.10 Million	0.136x	+1573.59%
2022-12-31	CN¥1.61 Billion ≈ $235.65 Million	CN¥13.04 Million ≈ $1.91 Million	0.008x	-87.62%
2021-12-31	CN¥1.27 Billion ≈ $185.24 Million	CN¥82.85 Million ≈ $12.12 Million	0.065x	-31.94%
2020-12-31	CN¥1.18 Billion ≈ $172.94 Million	CN¥113.64 Million ≈ $16.63 Million	0.096x	+56.20%
2019-12-31	CN¥1.07 Billion ≈ $156.69 Million	CN¥65.92 Million ≈ $9.65 Million	0.062x	+60.48%
2018-12-31	CN¥828.91 Million ≈ $121.30 Million	CN¥31.80 Million ≈ $4.65 Million	0.038x	-66.05%
2017-12-31	CN¥719.95 Million ≈ $105.35 Million	CN¥81.34 Million ≈ $11.90 Million	0.113x	-9.70%
2016-12-31	CN¥461.42 Million ≈ $67.52 Million	CN¥57.73 Million ≈ $8.45 Million	0.125x	-30.78%
2015-12-31	CN¥365.71 Million ≈ $53.51 Million	CN¥66.10 Million ≈ $9.67 Million	0.181x	+167.95%
2014-12-31	CN¥299.77 Million ≈ $43.87 Million	CN¥20.22 Million ≈ $2.96 Million	0.067x	-65.66%
2013-12-31	CN¥240.97 Million ≈ $35.26 Million	CN¥47.34 Million ≈ $6.93 Million	0.196x	--

About Chongqing Pharscin Pharmaceutical Co Ltd

SHE:002907 China Drug Manufacturers - Specialty & Generic

Market Cap

$812.73 Million

CN¥5.55 Billion CNY

Market Cap Rank

#9994 Global

#2681 in China

Share Price

CN¥13.30

Change (1 day)

+10.01%

52-Week Range

CN¥11.69 - CN¥20.74

All Time High

CN¥42.89